Pancreatic Cancer
Conditions
Keywords
HCP-Guided Exercise
Brief summary
Pilot study evaluating the feasibility of a 2-4 week health care provider guided exercise intervention prior to surgery for pancreatic cancer.
Interventions
BEHAVIORALHCP-Guided Exercise Training Program
Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity). Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity. The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR).
Sponsors
NYU Langone Health
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Willingness and ability to participate in the study procedures 2. Pathologically confirmed pancreatic cancer 3. Candidate for neoadjuvant therapy followed by surgical resection with potentially curative intent. Note: There is no limitation on duration of neoadjuvant therapy. 4. Planned to have at least 2 weeks after completing the last neoadjuvant therapy and surgery 5. Over the age of 18 6. Ability to engage in physical activity as determined by physiatrist review after completion of the Physical Activity Readiness questionnaire (PAR-Q) exercise survey and chart review 7. Agree to study blood draws and tissue collection
Exclusion criteria
1. Evidence of metastatic disease 2. Inability to complete physical activity due to recent injury or surgery 3. Uncontrolled heart disease limiting physical activity 4. Participation in another interventional trial that excludes participation in this protocol 5. Subjects who anticipate undergoing a procedure during the course of the trial that will render them unable to engage in physical activity for more than 48 hours 6. Pregnant subjects 7. Individuals who lack the capacity to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention | Up to Week 4 | Compliance with HCP exercise intervention is defined as successful completion of at least 150 minutes of weekly moderate-to-intense physical activity over a minimum of 2 weeks for every week of the prescribed intervention (2, 3 or 4 weeks). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants who Experience an Event that Leads to Delay in Surgical Resection | Up to Week 4 | — |
| Change in Number of Tumor-Infiltrating CD8-Positive T Cells | Baseline, Final Study Visit (Between Weeks 2-4) | Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of cluster designation 8 (CD8)-positive T cells. |
| Change in Number of Tumor-Infiltrating CD8-Positive T Cells Expressing IL-15Ra | Baseline, Final Study Visit (Between Weeks 2-4) | Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of CD8-positive T cells expressing Interleukin 15 Receptor Alpha Subunit (IL-15Ra). |
| Change in Number of Tumor-Infiltrating CD8-Positive T Cells Expressing GZMB | Baseline, Final Study Visit (Between Weeks 2-4) | Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of CD8-positive T cells expressing Granzyme B (GZMB). |
| Change in Number of Tumor-Infiltrating CD8-Positive T Cells Expressing CD3 | Baseline, Final Study Visit (Between Weeks 2-4) | Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of CD8-positive T cells expressing cluster designation 3 (CD3). |
| Number of Participants who Experience Adverse Events (AEs) | Up to Week 4 | AEs defined as any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. |
| Time Spent in Moderate-to-Vigorous Physical Activity (MVPA) | Up to Week 4 | Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms. Moderate Activity is defined as between 3.00 and 5.99 metabolic equivalents (METs). Vigorous Activity is defined as at least 6.00 METs. MET is defined as the ratio of the work metabolic rate to the resting metabolic rate. |
| Time Spent in Sedentary Behavior | Up to Week 4 | Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms. Sedentary Behavior is defined as less than 0.11 metabolic equivalents (METs). MET is defined as the ratio of the work metabolic rate to the resting metabolic rate. |
| Average Daily MET Rates | Up to Week 4 | Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms. MET is defined as the ratio of the work metabolic rate to the resting metabolic rate. Light intensity activities are defined as less than 3 METs, moderate intensity activities are defined as between 3 and 5.99 METs, and vigorous intensity activities are defined as 6 METs or greater. |
| Total Physical Activity Energy Expenditure | Up to Week 4 | Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms. Expressed in kcal/day. |
| Minutes Spent in Rapid Eye Movement (REM) Sleep | Up to Week 4 | Monitored using ActiGraph Centrepoint Insight Watch. |
| Change in Number of Circulating CD8-Positive T Cells Expressing IL-15Ra as Assessed by Flow Cytometry | Baseline, Final Study Visit (Between Weeks 2-4) | Flow cytometry conducted on patient blood samples to assess number of circulating CD8-positive T cells expressing Interleukin 15 Receptor Alpha Subunit (IL-15Ra). |
Countries
United States
Outcome results
None listed